Updated
This is a stat-stack — a single page of scannable CBD stats with full sources. Great for journalists, creators and curious shoppers. Click Copy citation to grab a ready-made reference.
Quick links: U.S. Usage & Prevalence · Demographics · Reasons & Behaviors · Spending & Purchase Patterns · Formats & Categories · Retail & E-Commerce · Pets · Market Size & Forecasts · All Sources · FAQ
Explore our education hub: CBD Education Center · Shop: THC-Free Oils, Gummies & Creams
U.S. Usage & Prevalence
- Past-year CBD use (U.S., 2022): ~20.6% of adults reported CBD use in the prior 12 months (peer-reviewed, nationally representative).
- Co-use with cannabis: ~63% of U.S. CBD users also used cannabis (2022 data).
- Earlier benchmark (2019): 14% of U.S. adults said they used CBD products.
- Past-year trend (survey study): ~21% CBD use prevalence; authors note an increase vs 2019 Gallup’s 14%.
- Ever-used (lifetime) indicator: Consumer survey cites ~33% of Americans have tried CBD at least once.
Demographics
- Gender: CBD use odds were higher among women in national models (AOR≈1.4 for CBD-only vs cannabis-only use).
- Race/ethnicity: Use was significantly lower among Black and Hispanic adults vs non-Hispanic White adults, controlling for covariates.
- Age pattern (2019 Gallup): Usage skews younger (e.g., 20% for 18–29; 8% for 65+).
- “Tried CBD” by age (2019): 40% of people in their 20s had tried CBD vs 15% of people 60+.
Reasons & Behaviors
Self-reported reasons are not medical claims or proof of efficacy.
- Top reasons (survey): Pain/inflammation (~64%), anxiety (~49%), insomnia (~42%).
- Medication overlap: ~36% reported using CBD alongside a prescription medication (survey).
- Frequency & first purchase: ~9% daily users; ~19% “as needed”; ~59% said their first purchase was planned (survey).
- Non-user barriers: ~25% cost; ~18% lack of studies; ~14% distrust in claims (survey).
- Formats tried (survey): Oils/tinctures and gummies are the most commonly tried products among U.S. consumers.
- Perceived effectiveness (2019): Many U.S. users reported subjective improvement for issues like anxiety/sleep (self-reported perceptions).
Spending & Purchase Patterns
- Monthly spend bands (survey): Many U.S. buyers report budgets in the $20–$80/month range depending on format and frequency.
- Budget sensitivity: Roundups of U.S. survey data show many regular users report < $50/month spend; a sizable minority spend $50+.
- Planned vs impulse: ~59% reported their first CBD purchase was planned rather than impulse (survey).
- Value sensitivity: Discounts and bundle pricing were commonly cited as helping buyers manage monthly CBD budgets (survey context).
Formats & Categories
- Formats: Gummies and tinctures are core consumer formats; topicals are strong for active/recovery shoppers (analyst overview).
- Gummies acceleration: One segmentation forecast expects gummies/confectionery to grow at ~30% CAGR to 2030 (model-based).
- Product types tried: Oils/tinctures and gummies lead, with capsules and topicals also widely tried among U.S. consumers (survey).
Retail & E-Commerce
- Channels (U.S. context): DTC brand sites & specialty retail remain core B2C channels; pharmacies/wellness clinics contribute meaningful share (analyst view).
- Offline vs online (oil-segment model): Projection shows offline channels capturing ~56% of share by 2035.
- Where people buy (2019 context): Consumers reported purchasing CBD both online and in-store (pharmacies, specialty shops, dispensaries), reflecting mixed-channel behavior.
Shop Kyoto Botanicals: USDA-Organic, THC-Free Oils · CBD Sports Cream & Recovery
Pets
- Dog owners & CBD: AKC summary notes just over one-third of dog owners purchased some type of CBD product for their dog, especially treats and shampoo (usage contexts listed).
- CBD pet treats: APPA data cited that 26% of U.S. dog owners purchased CBD treats in 2022 (vs 24% in 2020).
- CBD pet growth (3-yr): CBD pet supplement sales up +236% and CBD pet food sales up +377% over three years (NielsenIQ).
Market Size & Forecasts
- Global CBD market (2025→2030): ~$10.68B (2025) to ~$22.05B (2030); CAGR ~15.8% (analyst model).
- Incremental growth (’24–’29): Model projects ~$56.5B increase; CAGR ~24.8%.
- U.S. share (consumer health): U.S. estimated around 61% of global CBD consumer health market (2024 context); modeled to ~$34.7B by 2034.
- Global CBD market (alt model): ~$10.38B (2025) to ~$38.97B (2034); CAGR ~15.8%.
All Sources (quick access)
- Choi et al., 2024 — Prevalence of CBD use (SciDirect)
- Choi et al., 2024 — PubMed record
- Wilson-Poe et al., 2023 — Past-year prevalence (PMC)
- Gallup — 14% of Americans use CBD (2019)
- Consumer Reports — CBD Goes Mainstream (2019)
- SingleCare — CBD statistics (overview)
- SingleCare — CBD Survey detail
- DataTrek Research — Usage by demographics
- Grand View Research — Cannabidiol Market
- Mordor Intelligence — CBD Market Segmentation
- Technavio — CBD Market Forecast
- Precedence — CBD Consumer Health Market
- Precedence — Cannabidiol Market (global)
- AKC — Pet Spending Trends (CBD mention)
- APPA stat via Meat+Poultry — CBD pet treats
- Pet Food Processing — NielsenIQ CBD pet growth
Keep exploring: How Organic CBD Tinctures Support Holistic Wellness · CBD Sports Cream & Recovery · USDA-Organic, THC-Free Oils
CBD Statistics — Frequently Asked Questions
How often is this statistics page updated?
We aim to refresh annually and add interim updates as new reports publish. The “Updated” badge near the top shows the latest date.
Can I cite these stats in my article or presentation?
Yes — each bullet has a Copy citation button and a visible source link.
Why do numbers vary between sources?
Methodologies differ (sample frames, time windows, category definitions, and modeling). Treat forecasts as ranges.
Where can I find product COAs and quality information?
Every Kyoto Botanicals product has batch-specific third-party lab results. Start here: The Key to High-Quality CBD Products.
Are Kyoto Botanicals products THC-free?
Yes. We focus on broad-spectrum, THC-free products with USDA-certified organic carrier oils. Learn more: Why THC-Free Matters.
Methodology: We aggregate peer-reviewed literature and widely referenced market reports; percentages reflect self-reported consumer behavior unless otherwise noted. Informational only; not medical advice. Check local laws.